Mineralys Therapeutics Inc (MLYS) Stock Price, Quote & News

Company Profile

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2...

Industry: Biotechnology

Sector: Healthcare

Phone: 888 378 6240

Website: mineralystx.com

Address:

150 N. Radnor Chester Rd., Suite F200, Radnor, United States

JarvisFlow Sep. 11 at 1:00 PM

Wells Fargo updates rating for Mineralys Therapeutics ( $MLYS ) to Overweight, target set at 26 → 50.

0 · Reply

SnoopDawg Sep. 10 at 12:23 PM

$MLYS sure would be nice to know what's going on lol. Better to be lucky than good I guess.

0 · Reply

jaypeezy99 Sep. 9 at 7:46 PM

$MLYS Someday someone will have to explain this one to me... Offering at 25.50... they should have waited until 40...

0 · Reply

jaypeezy99 Sep. 9 at 6:46 PM

$MLYS I guess this is going to go up forever then... might have to wait for my short entry... I keep coming back day after day, but no joy!

0 · Reply

anachartanalyst Sep. 9 at 6:02 PM

$MLYS https://anachart.com/wp-content/uploads/ana_temp/1757440921_soc-img.jpg

0 · Reply

JarvisFlow Sep. 9 at 5:40 PM

Goldman Sachs has adjusted their stance on Mineralys Therapeutics ( $MLYS ), setting the rating to Buy with a target price of 32 → 52.

0 · Reply

Harichandra100 Sep. 9 at 4:08 PM

$MLYS 190% up in 10days offering and insiders buying was at 25$ , previously insiders bought at 13$ they are sitting on 190% profit, surprised who is buying still options, buyer will exhaust

0 · Reply

cabottrailcrew Sep. 9 at 4:02 PM

$MLYS Insiders bought the offering at $25.5 - probably no one in the market is buying it. Major dump coming soon.

0 · Reply

Im_a_realist Sep. 9 at 1:13 PM

$MLYS The offering was at $25.50 but somehow people think it's worth more.

0 · Reply

Derek_Zoolander Sep. 8 at 6:13 PM

$MLYS should fall back to reality soon around $30-$33 …

1 · Reply

Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need

Sep 4, 2025, 4:01 PM EDT - 8 days ago

Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 3, 2025, 8:17 AM EDT - 10 days ago

Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

BRKR

Sep 2, 2025, 9:33 PM EDT - 10 days ago

Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock

Sep 2, 2025, 4:01 PM EDT - 10 days ago

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

Aug 13, 2025, 12:16 AM EDT - 4 weeks ago

Mineralys Therapeutics, Inc. (MLYS) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 4 weeks ago

Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 4, 2025, 4:05 PM EDT - 5 weeks ago

Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025

Jun 30, 2025, 11:17 AM EDT - 2 months ago

Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat

Jun 17, 2025, 9:57 AM EDT - 3 months ago

Mineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive Patients With Chronic Kidney Disease, Stock Jumps

Jun 17, 2025, 7:00 AM EDT - 3 months ago

Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria

May 24, 2025, 4:30 AM EDT - 4 months ago

Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)

May 20, 2025, 8:00 AM EDT - 4 months ago

Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection

May 12, 2025, 8:20 PM EDT - 4 months ago

Mineralys Therapeutics, Inc. (MLYS) Q1 2025 Earnings Conference Call Transcript

May 12, 2025, 4:05 PM EDT - 4 months ago

Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 7, 2025, 8:00 AM EDT - 4 months ago

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

May 5, 2025, 4:05 PM EDT - 4 months ago

Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025

Apr 23, 2025, 5:23 PM EDT - 5 months ago

Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)

Mar 29, 2025, 2:30 PM EDT - 5 months ago

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)

Mar 25, 2025, 8:00 AM EDT - 6 months ago

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

Mar 18, 2025, 4:01 PM EDT - 6 months ago

Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

Mar 17, 2025, 8:00 AM EDT - 6 months ago

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo

Mar 12, 2025, 8:36 AM EDT - 6 months ago

Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

LDI MOMO

Mar 11, 2025, 10:20 PM EDT - 6 months ago

Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock

Mar 10, 2025, 6:25 PM EDT - 6 months ago

Mineralys: Prospects Just Got Better With Successful Pivotal Data Readouts

Mar 10, 2025, 1:50 PM EDT - 6 months ago

Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate

Mar 10, 2025, 1:09 PM EDT - 6 months ago

Dow Tumbles Over 600 Points; Mineralys Therapeutics Shares Spike Higher

Mar 10, 2025, 7:12 AM EDT - 6 months ago

Mineralys Therapeutics' blood pressure drug meets goal in trials

Mar 10, 2025, 7:00 AM EDT - 6 months ago

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

Mar 7, 2025, 4:01 PM EST - 6 months ago

Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET

Feb 12, 2025, 1:38 PM EST - 7 months ago

Mineralys Therapeutics, Inc. (MLYS) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 7:00 AM EST - 7 months ago

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Feb 5, 2025, 4:05 PM EST - 7 months ago

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025

Jan 19, 2025, 8:18 PM EST - 8 months ago

Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension

Nov 11, 2024, 10:00 PM EST - 10 months ago

Mineralys Therapeutics, Inc. (MLYS) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 4:05 PM EST - 10 months ago

Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 5, 2024, 4:05 PM EST - 11 months ago

Mineralys Therapeutics to Participate in Upcoming Investor Conferences

Nov 4, 2024, 4:05 PM EST - 11 months ago

Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024

Oct 24, 2024, 11:00 AM EDT - 11 months ago

The Schall Law Firm Invites Investors To Join An Inquiry Into Mineralys Therapeutics, Inc. For Securities Fraud

Oct 22, 2024, 11:00 AM EDT - 11 months ago

The Schall Law Firm Encourages Investor Participation In An Inquiry Into Mineralys Therapeutics, Inc. For Securities Fraud

Oct 20, 2024, 11:00 AM EDT - 11 months ago

The Schall Law Firm Encourages Investors To Join An Inquiry Into Mineralys Therapeutics, Inc. For Securities Fraud

Oct 18, 2024, 11:00 AM EDT - 11 months ago

The Schall Law Firm Encourages Investors To Take Part In An Inquiry Into Mineralys Therapeutics, Inc. For Securities Fraud

Oct 16, 2024, 11:00 AM EDT - 11 months ago

The Schall Law Firm Encourages Investor Participation In An Inquiry Into Mineralys Therapeutics Inc For Securities Fraud

Oct 14, 2024, 11:00 AM EDT - 11 months ago

The Schall Law Firm Encourages Investors To Take Part In An Inquiry Into Mineralys Therapeutics Inc For Possible Securities Fraud

Oct 10, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Encourages Investor Participation In An Inquiry Into Mineralys Therapeutics Inc For Possible Securities Fraud

JarvisFlow Sep. 11 at 1:00 PM

Wells Fargo updates rating for Mineralys Therapeutics ( $MLYS ) to Overweight, target set at 26 → 50.

0 · Reply

SnoopDawg Sep. 10 at 12:23 PM

$MLYS sure would be nice to know what's going on lol. Better to be lucky than good I guess.

0 · Reply

jaypeezy99 Sep. 9 at 7:46 PM

$MLYS Someday someone will have to explain this one to me... Offering at 25.50... they should have waited until 40...

0 · Reply

jaypeezy99 Sep. 9 at 6:46 PM

$MLYS I guess this is going to go up forever then... might have to wait for my short entry... I keep coming back day after day, but no joy!

0 · Reply

anachartanalyst Sep. 9 at 6:02 PM

$MLYS https://anachart.com/wp-content/uploads/ana_temp/1757440921_soc-img.jpg

0 · Reply

JarvisFlow Sep. 9 at 5:40 PM

Goldman Sachs has adjusted their stance on Mineralys Therapeutics ( $MLYS ), setting the rating to Buy with a target price of 32 → 52.

0 · Reply

Harichandra100 Sep. 9 at 4:08 PM

$MLYS 190% up in 10days offering and insiders buying was at 25$ , previously insiders bought at 13$ they are sitting on 190% profit, surprised who is buying still options, buyer will exhaust

0 · Reply

cabottrailcrew Sep. 9 at 4:02 PM

$MLYS Insiders bought the offering at $25.5 - probably no one in the market is buying it. Major dump coming soon.

0 · Reply

Im_a_realist Sep. 9 at 1:13 PM

$MLYS The offering was at $25.50 but somehow people think it's worth more.

0 · Reply

Derek_Zoolander Sep. 8 at 6:13 PM

$MLYS should fall back to reality soon around $30-$33 …

1 · Reply

jaypeezy99 Sep. 8 at 3:55 PM

$MLYS Going to be a $3BN MC which hasn't sold as much as a paperclip 😂

0 · Reply

Jakeipedia Sep. 8 at 2:35 PM

$MLYS 😊

0 · Reply

Harichandra100 Sep. 8 at 2:34 PM

$MLYS every day new high, already 140% in 4 days trade , valuation is out of space as it got FDA approval

0 · Reply

jaypeezy99 Sep. 8 at 2:07 PM

$MLYS still grinding I see… 🤣

0 · Reply

Quantumup Sep. 8 at 1:06 PM

H.C. Wainwright reiterated $MLYS Buy/$42. $AZN H.C. Wainwright said:

0 · Reply

JarvisFlow Sep. 8 at 11:30 AM

HC Wainwright & Co. updates rating for Mineralys Therapeutics ( $MLYS ) to Buy, target set at 42.

0 · Reply

Rajankduggy Sep. 7 at 11:20 PM

$MLYS This week is the week this pig gets shorted by me

0 · Reply

Karellceballos1 Sep. 6 at 7:31 PM

$MLYS

0 · Reply

Harichandra100 Sep. 5 at 8:45 PM

$MLYS offering was made at 25$ it kept pumped by options and other day traders. 130% in 4 days . Many have sold in big chuck silently. This will fall back to 25$ soon .

0 · Reply

jaypeezy99 Sep. 5 at 7:45 PM

$MLYS Like clockwork... I'm not bullish but going long at 3pm each day is a guaranteed gain...

0 · Reply

jaypeezy99 Sep. 5 at 2:55 PM

$MLYS Have been waiting to short this, and thought it was going to break trend today, but nope... still chugging along...

0 · Reply

FiercePamela Sep. 5 at 3:49 AM

VEEE--> Don't miss this one! Has double digit potential, known runner and now with 0 shares to borrow plus with News yesterday this is looking like a parabolic setup. With Just 1.5M float this has the potential to go big, so be early and lets bank on this! $MLYS $NCI $RAPT $MGIH

0 · Reply

Market Cap	2.46B
Revenue (ttm)	0.00
Net Income (ttm)	-177.81M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,268,200
Avg Vol	1,491,330
Day's Range	N/A - N/A
Shares Out	66.30M
Stochastic %K	88%
Beta	-0.29
Analysts	Strong Sell
Price Target	$40.75